CL2013001978A1 - Compuestos biciclicos o oxabiciclicos nitrogenados, antagonistas no competitivos moduladores de receptores nicotinicos; composicion farmaceutica que los comprende; uso de los compuestos para el tratamiento o la prevencion de hipertension, adiccion a la nicotina, depresion o ansiedad, detrioros cognitivos, inflamacion. - Google Patents

Compuestos biciclicos o oxabiciclicos nitrogenados, antagonistas no competitivos moduladores de receptores nicotinicos; composicion farmaceutica que los comprende; uso de los compuestos para el tratamiento o la prevencion de hipertension, adiccion a la nicotina, depresion o ansiedad, detrioros cognitivos, inflamacion.

Info

Publication number
CL2013001978A1
CL2013001978A1 CL2013001978A CL2013001978A CL2013001978A1 CL 2013001978 A1 CL2013001978 A1 CL 2013001978A1 CL 2013001978 A CL2013001978 A CL 2013001978A CL 2013001978 A CL2013001978 A CL 2013001978A CL 2013001978 A1 CL2013001978 A1 CL 2013001978A1
Authority
CL
Chile
Prior art keywords
compounds
oxabicyclic
nitrogenated
anxiety
bicyclic
Prior art date
Application number
CL2013001978A
Other languages
English (en)
Inventor
Srinivasa Rao Akireddy
Scott R Breining
Matt S Melvin
Srinivasa V Murthy
Anatoly A Mazurov
Balwinder Singh Bhatti
Jon-Paul Strachan
Ronald Joseph Heemstra
Todd Showalter
Yunde Xiao
Philip S Hammond
Lan Miao
David Kombo
Daniel Yohannes
Jason Speake
Original Assignee
Targacept Inc ;
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc ; filed Critical Targacept Inc ;
Publication of CL2013001978A1 publication Critical patent/CL2013001978A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/40Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/36Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/44Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CL2013001978A 2011-01-07 2013-07-05 Compuestos biciclicos o oxabiciclicos nitrogenados, antagonistas no competitivos moduladores de receptores nicotinicos; composicion farmaceutica que los comprende; uso de los compuestos para el tratamiento o la prevencion de hipertension, adiccion a la nicotina, depresion o ansiedad, detrioros cognitivos, inflamacion. CL2013001978A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161430640P 2011-01-07 2011-01-07

Publications (1)

Publication Number Publication Date
CL2013001978A1 true CL2013001978A1 (es) 2013-11-04

Family

ID=46457959

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001978A CL2013001978A1 (es) 2011-01-07 2013-07-05 Compuestos biciclicos o oxabiciclicos nitrogenados, antagonistas no competitivos moduladores de receptores nicotinicos; composicion farmaceutica que los comprende; uso de los compuestos para el tratamiento o la prevencion de hipertension, adiccion a la nicotina, depresion o ansiedad, detrioros cognitivos, inflamacion.

Country Status (16)

Country Link
US (1) US20140288169A1 (es)
EP (1) EP2661421A2 (es)
JP (1) JP2014510026A (es)
KR (1) KR20140038361A (es)
CN (1) CN103402971A (es)
BR (1) BR112013017405A2 (es)
CA (1) CA2823848A1 (es)
CL (1) CL2013001978A1 (es)
CO (1) CO6821933A2 (es)
IL (2) IL227319A0 (es)
MX (1) MX2013007952A (es)
PE (1) PE20140873A1 (es)
PH (1) PH12013501453A1 (es)
RU (1) RU2013136851A (es)
SG (1) SG191884A1 (es)
WO (1) WO2012094437A2 (es)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3514486A (en) * 1968-05-23 1970-05-26 Miles Lab 3-isopropylnorbornanamine
US4883888A (en) * 1984-07-13 1989-11-28 The Procter & Gamble Company Oxa-fenchyl amines useful for preparing high intensity sweeteners
CA2194702A1 (en) * 1994-07-11 1996-01-25 Stephen A. Munk Conformationally rigid bicyclic and adamantane derivatives useful as .alpha.2-adrenergic blocking agents
US5986142A (en) * 1997-09-23 1999-11-16 Poli Industria Chimica Spa Process for preparing bicycloheptanamine compounds
CN1612732A (zh) * 2001-08-29 2005-05-04 恩德制药公司 止痛剂和使用方法
US20080058345A1 (en) * 2004-01-06 2008-03-06 Tony George Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
KR20070034524A (ko) * 2004-05-28 2007-03-28 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조정자
JP2008521821A (ja) * 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
EP1863490A2 (en) * 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Muscarinic modulators
JPWO2006104280A1 (ja) * 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤
TW200738676A (en) * 2005-06-20 2007-10-16 Schering Corp Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
CA2622375A1 (en) * 2005-09-17 2007-03-22 Speedel Experimenta Ag Alcanoic acid amides substituted by saturated o-heterocycles
WO2007071662A1 (en) * 2005-12-20 2007-06-28 Solvay Pharmaceuticals B.V. 4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
TW200730500A (en) * 2005-12-20 2007-08-16 Solvay Pharm Bv 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
CN101778838A (zh) * 2007-05-24 2010-07-14 惠氏有限责任公司 作为组胺-3拮抗剂的氮杂环基苯甲酰胺衍生物
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
CN102448303A (zh) * 2009-05-29 2012-05-09 Xl特拉有限公司 脱水戊糖醇的缩酮酯和它们的用途
WO2013026852A2 (en) * 2011-08-22 2013-02-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Derivatives of mecamylamine

Also Published As

Publication number Publication date
IL230334A0 (en) 2014-03-06
CO6821933A2 (es) 2013-12-31
CN103402971A (zh) 2013-11-20
KR20140038361A (ko) 2014-03-28
PE20140873A1 (es) 2014-08-13
SG191884A1 (en) 2013-08-30
WO2012094437A3 (en) 2012-11-01
WO2012094437A2 (en) 2012-07-12
IL227319A0 (en) 2013-09-30
RU2013136851A (ru) 2015-02-20
PH12013501453A1 (en) 2013-08-28
CA2823848A1 (en) 2012-07-12
MX2013007952A (es) 2013-08-21
JP2014510026A (ja) 2014-04-24
EP2661421A2 (en) 2013-11-13
US20140288169A1 (en) 2014-09-25
BR112013017405A2 (pt) 2016-10-04

Similar Documents

Publication Publication Date Title
CL2014003278A1 (es) Compuestos derivados de tetrahidropirazolopirimidina, antagonistas o inhibidores de receptores similares a toll 7 y/u 8; mezcla racemica; composcion farmaceutica que los comprende; y metodo para el tratamiento de lupus eritematoso sistemico o lupus.
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
MX387702B (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
BR112014001279A2 (pt) composto, uso do composto, composição farmacêutica, e, método para tratar um indivíduo que sofre com um distùrbio mediado pela tirosina cinase de bruton (btk)
CL2014000450A1 (es) Compuestos derivados de n-(heteroarilmetil)-6-[(2-heteroarilciclopropil)metoxi]pririmidin-4-amina, inhibidores de pde10; composicion farmaceutica; y su uso para el tratamiento de un trastorno seleccionado de trastornos psicóticos, delirantes, entre otros.
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
ECSP16078779A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2008002708A1 (es) Compuestos derivados de azaciclilisoquinolinona e isoindolinona, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuestos; y uso del compuesto para el tratamiento de un trastorno cognitivo,
CL2015001483A1 (es) Compuestos derivados de hidroxiquinolina y otros heterociclos nitrogenados, antagonistas de los receptores muscarínicos y agonistas del receptor beta2 adrenérgico; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento o prevencion del asma, bronquitis cronica o epoc.
WO2014066799A3 (en) Modulators of resistant androgen receptor
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
DK3303323T3 (da) Heterocykliske forbindelser af 3,3-difluorpiperidincarbamat som NR2B-NMDA-receptorantagonister
BR112014016736A8 (pt) composto, composição farmacêutica, método para tratamento, uso de um composto e invenção
CR20160042A (es) ANTAGONISTAS DE V1a PARA TRATAR TRASTORNOS DEL SUEÑO POR CAMBIO DE FASE
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?